Zhitong Finance App News, Aoxiang Pharmaceutical (603229.SH) released its 2023 annual performance report. During the reporting period, the company achieved operating income of 817 million yuan, an increase of 6.83%; net profit attributable to shareholders of listed companies was 254 million yuan, an increase of 7.87% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 243 million yuan, an increase of 6.57% year on year; basic income per share was 0.43 yuan. The company plans to distribute a cash dividend of RMB 1.29 yuan (tax included) for every 10 shares to all shareholders by transferring share capital from a capital reserve fund Transfer 4 shares for every 10 shares to all shareholders.